Abzena secures ADC manufacturing services contract
Following the initial chemistry development, Abzena subsequently developed a cell line that will now be used to produce the antibody at its GMP manufacturing facility. Abzena will also conduct GMP production of the ADC payload reagent and the conjugation process to create the ADC for initial clinical study.Read More
New target for the treatment of Cardiovascular Fibrosis developed by Enleofen Bio, with support from Abzena, featured in ‘Nature’ article
Abzena will also support Enleofen Bio through the development of alternative strategies to block IL11 signalling. Abzena’s wide range of protein engineering technologies will help to translate findings from successful proof-of-concept studies in preclinical models of disease to the clinic.Read More
Abzena and Telix sign licence agreement for Abzena’s Prostate-Specific Membrane Antigen Antibodies
Under the terms of the Agreement, Abzena has granted Telix an exclusive worldwide, royalty bearing, sub-licensable licence to its prostate-specific membrane antigen (‘PSMA’) antibodies in the field of radio-immunoconjugation.Read More
Technologies and Solutions
Abzena provides proprietary technologies and complementary solutions to organisations involved in the development of biopharmaceutical products.
Latest News and Events
Abzena presents its latest research and exhibits at events all over the world.
Find out where we are next and our latest news below.
Abzena takes on new facilities in Cambridge, UK and San Diego
GTC Bio ImmunoTX Summit
San Diego, CA, USA
30 January 2018
Babraham Bioscience Technologies “Technology Development Laboratory” (TDL) moves to Abzena
Envigo 8th Annual Biologics Symposia, USA
Plainsboro, NJ, USA
21 February 2018
Resources and Downloads
Find our latest videos, brochures and fact sheets in our resources section.
Download our Brochure
Technology & Solutions BrochureDownload File
Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates
Antibody-drug conjugates (ADCs) are a promising class of anticancer agents which have undergone substantial development…Read More
Manufacturing & Cell Line Development at Abzena
Abzena has extensive experience in cGMP and non-GMP production for recombinant proteins, antibodies and conjugates…